Innovent Biologics
Innovent Biologics, Inc. is a Chinese biopharmaceutical enterprise that researches, develops, manufactures, and commercializes innovative medicines for the treatment of major life-threatening diseases. The company directs its scientific focus primarily toward oncology, metabolic diseases, autoimmune disorders, and ophthalmology. Its principal product offerings encompass monoclonal antibodies, immunotherapies, and other biologic therapeutic products approved for clinical application. Revenue is driven primarily by the commercial sale of approved pharmaceutical products within domestic markets, alongside licensing fees and collaborative development agreements with global pharmaceutical partners. The primary end markets comprise hospitals, clinics, and patients requiring advanced biologic therapies. As a prominent participant in the expanding Asian biotechnology sector, the enterprise maintains substantial research and manufacturing capabilities. Headquartered in Suzhou, China, Innovent Biologics, Inc. is publicly listed on the Hong Kong Stock Exchange.
44 of the funds FundTelligence covers report a position in Innovent Biologics.
- Legal name
- Innovent Biologics Inc
- Sector
- Health Care
- Country
- China
- Funds holding it
- 44
Funds holding Innovent Biologics
- Jupiter China Equity Fund — Jupiter · 2.94 % (largest positions only, October 2026)
- Templeton China Fund — Franklin Templeton · 2.66 % (full portfolio disclosed, September 2026)
- Lannebo Global Growth — Lannebo · 2.08 % (full portfolio disclosed, June 2026)
- BNP Emerging Equity — BNP Paribas · 1.86 % (full portfolio disclosed, June 2026)
- Nordea Emerging ex China Sustainable Stars Equity Fund — Nordea Funds · 1.51 % (full portfolio disclosed, September 2026)
- Nordea Emerging Sustainable Stars — Nordea Funds · 1.5 % (full portfolio disclosed, September 2026)
- BNP China Equity — BNP Paribas · 1.48 % (full portfolio disclosed, June 2026)
- Nordea Asian Sustainable Stars — Nordea Funds · 1.47 % (full portfolio disclosed, September 2026)
Showing the 8 largest of 44 funds holding it.